Phase I trial of pazopanib in patients with advanced cancer. - Wikidata - awgldk - TriplyDB

Phase I trial of pazopanib in patients with advanced cancer.

Phase I trial of pazopanib in patients with advanced cancer.

http://www.wikidata.org/entity/Q45976168

about

Pazopanib in the management of advanced soft tissue sarcomas Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Pazopanib in sarcomas: expanding the PALETTE Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Developmental therapeutics for inflammatory breast cancer: Biology and translational directions Neoadjuvant Therapy in Differentiated Thyroid Cancer Pazopanib in the treatment of soft tissue sarcoma Safety and tolerability of pazopanib in the treatment of renal cell carcinoma Pazopanib, a new therapy for metastatic soft tissue sarcoma The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.Computational repositioning and preclinical validation of pentamidine for renal cell cancer.Pazopanib: approval for soft-tissue sarcoma.Effect of pazopanib on tumor microenvironment and liposome delivery The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma Experimental approaches for the treatment of malignant gliomas.Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors Pazopanib for the treatment of patients with advanced renal cell carcinoma In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.Targeting angiogenesis in advanced cervical cancer.Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.Pazopanib for the treatment of soft-tissue sarcoma.Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.

P2860

Q26746205-CEE1A54B-DD79-4A25-A558-27D2393C1833 Q26751274-BE660A29-20DB-4B28-843D-B97EB26185F1 Q26825050-2C45225B-E6EC-43F9-954C-0FF46B9BB956 Q27011840-80EF726E-EE09-461F-B610-94BC6A323B77 Q27024235-10415ECD-5F1B-45B7-8B06-DBE1FAD4EA0E Q27852954-45C4A62E-63BC-45A0-85D3-27F4709435DE Q28075322-12F38D7C-55B1-47E6-B6D8-78D19CF6CDC7 Q28078879-ADB8D0B1-D411-4658-8F3F-B79DF14210B6 Q28269229-E1E28117-9515-4D6E-BCBD-3C47877D8595 Q28272429-F914630F-0BB8-42EF-B95A-41B08374A708 Q28287163-F33E460A-9544-4CBD-A708-1F0AC38BBF49 Q28744228-61908835-FFEF-4C95-AE62-AF00C73B26A9 Q30396736-A0C2C8E0-6866-4609-B0BD-4339E12AB682 Q33404877-CE6F2AC0-E224-46AF-BCFB-BB108C3B5C07 Q33412909-6C8A85EA-E23E-4325-88A3-A9A7EB8122CD Q33430940-AE622409-B61F-42DB-8BDB-5F43C3004211 Q33590458-1D2C4A30-0508-4DD5-BD07-B830CB29B830 Q33633424-2322A83E-69BD-4B37-8975-06749392C458 Q33826472-FC2C0166-671A-4B9C-A79A-B8CB65B831B2 Q33875574-471127C4-BB5B-47E0-B109-654BE2E13DD4 Q33885782-E210331A-C237-44B0-A32A-5DB8908804FF Q34018204-5F06BFC8-34B9-4A86-BE5B-8E9EF24A9C22 Q34052424-2E60CC8F-042F-4184-9922-C1145B8D5F3E Q34064359-767148EC-1D28-4BCC-B42C-8DC72B03E939 Q34127138-529FCA58-D17B-46FE-8DDF-B2E67E78D610 Q34129269-9A7DB527-DD06-4608-8550-5A56030DC60C Q34207205-FB463231-B680-445B-9002-56A3A6F402F1 Q34334533-4DD294C6-CC23-49D0-8688-E0B4A365994E Q34389368-2244D382-011A-4386-AE29-3FD655769091 Q34499668-A55E5F6D-719E-4D44-B5E3-47D880C20323 Q34645938-B0790376-F843-4AF6-B620-D47B20F869EE Q34659530-C0D13576-292D-4DE6-8615-4F746067777E Q34670026-1298C910-1E8A-4C49-B8EC-AFCCFB020FA8 Q35023367-AABC90A7-D50C-481A-9739-7CBD538F5097 Q35074974-14D06F43-6F58-431D-AE94-2ECC70314EC0 Q35212949-F56E7D78-5818-4395-BF4E-224E0511A722 Q35534962-CB457BEC-0E7B-4A7E-9B85-F4819DDC1D48 Q35583837-CDD83D10-3778-44A3-9211-441484C4F4F1 Q35584239-888E21AD-7850-436D-8D59-8484D1505E2C Q35599819-59E2308B-4034-4425-8694-DB8CA3D1407C

P2860

Phase I trial of pazopanib in patients with advanced cancer.

http://www.wikidata.org/entity/Q45976168

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Phase I trial of pazopanib in patients with advanced cancer.

@en

Phase I trial of pazopanib in patients with advanced cancer.

@nl

type

label

Phase I trial of pazopanib in patients with advanced cancer.

@en

Phase I trial of pazopanib in patients with advanced cancer.

@nl

prefLabel

Phase I trial of pazopanib in patients with advanced cancer.

@en

Phase I trial of pazopanib in patients with advanced cancer.

@nl

P1433

Q45976168-E375DA98-6B8B-4053-BA8F-571FC03B4483

P1476

Q45976168-A4E3CC5C-E535-4635-BD48-55EB78530480

P2093

Q45976168-121B8AE9-966B-43C1-84BE-22CA47068C98

Q45976168-14128DAB-B0E9-4DE5-B848-1897D0DCBE98

Q45976168-2EA1ECA5-91FD-4AB6-A3ED-03D5C87B1B8E

Q45976168-31D2D193-5228-46B3-9687-32FDC6CFB267

Q45976168-568ED729-C891-4EC0-A079-83EDC0729718

Q45976168-7E02B25B-C0B7-48FB-8F6B-6812F9045A0F

Q45976168-8B5065E5-2B3F-431E-9AD9-9084060C4E6E

Q45976168-A76E946B-C701-4C6A-8F84-DC098A861FFC

Q45976168-A8172B5C-ADBC-4149-BACE-50BBBFB11A18

P304

Q45976168-BC79C253-7809-427B-95C2-1D34581C8D92

P31

Q45976168-421028F6-D56A-4A71-8895-B023A77A8B81

P356

Q45976168-9B0E25D2-034A-4D9E-AE8E-D5CB2D3A634E

P407

Q45976168-EF4D325A-89A3-418C-A15D-E42B3CF85BC9

P433

Q45976168-3E997A2E-11E0-4950-AD4F-2921C4F98165

P478

Q45976168-5E8776FD-9475-458F-B515-8E4E65D7E326

P577

Q45976168-74B87F00-76E4-49BF-83D6-FC57BAE97C79

P698

Q45976168-F4F6CF4C-F2F1-443D-A6AD-15EB643FD90C

P921

Q45976168-E431251E-7E49-4921-888E-2F805C77123E

Q45976168-E59C9824-FF91-4D23-AE9A-499D94F73E20

P356

1078-0432.CCR-08-2740

P1433

Clinical Cancer Research

P1476

Phase I trial of pazopanib in patients with advanced cancer.

@en

P2093

A Benjamin Suttle

http://www.w3.org/2001/XMLSchema#string

Afshin Dowlati

http://www.w3.org/2001/XMLSchema#string

Diana M Gibson

http://www.w3.org/2001/XMLSchema#string

Elmar M Merkle

http://www.w3.org/2001/XMLSchema#string

Herbert I Hurwitz

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Hodge

http://www.w3.org/2001/XMLSchema#string

Lini Pandite

http://www.w3.org/2001/XMLSchema#string

Shawna Savage

http://www.w3.org/2001/XMLSchema#string

Shermini Saini

http://www.w3.org/2001/XMLSchema#string

P304

4220-4227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-2740

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19509175

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial